{"url_path":"/sec/bntc/10-q/2026/item-5","section_key":"item-5","section_title":"Item 5 Other Information","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/1808898/0001193125-26-222885-index.html","accession_number":"0001193125-26-222885","cik":"0001808898","ticker":"BNTC","issuer_name":"Benitec Biopharma Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1808898/0001193125-26-222885-index.html","primary_entity_key":"0001808898","primary_entity_name":"Benitec Biopharma Inc."},"word_count":44,"has_tables":true,"body_markdown":"Item 5. Other Information\n\nDuring the quarter ended March 31, 2026, none of our directors or officers adopted, modified, or terminated a “Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trading arrangement” as such terms are defined under Item 408 of Regulation S-K.\n\n37"}